NeuBase Therapeutics, Inc. financial data

Location
Pittsburgh, PA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2023 - 09 Nov 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 411 % -50.3%
Debt-to-equity 65.86 % +1.3%
Return On Equity -104 % -6.3%
Return On Assets -62.41 % +17.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3,729,206 shares
Common Stock, Shares, Outstanding 3,729,206 shares -88.7%
Common Stock, Value, Issued 373 USD -88.7%
Weighted Average Number of Shares Outstanding, Basic 2,757,576 shares +70.8%
Weighted Average Number of Shares Outstanding, Diluted 2,757,576 shares +70.8%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4,263,501 USD -80.1%
General and Administrative Expense 9,120,408 USD -23.2%
Operating Income (Loss) -15,265,679 USD +54.2%
Nonoperating Income (Expense) 1,535,621 USD +9.8%
Net Income (Loss) Attributable to Parent -13,730,058 USD +59.4%
Earnings Per Share, Basic -3 USD/shares +72%
Earnings Per Share, Diluted -3 USD/shares +72%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12,570,359 USD -45.7%
Assets, Current 13,352,032 USD -45.8%
Property, Plant and Equipment, Net 79,665 USD -96.3%
Operating Lease, Right-of-Use Asset 5,064,184 USD -9.8%
Assets 18,621,272 USD -43%
Accounts Payable, Current 258,644 USD -86%
Accrued Liabilities, Current 462,186 USD -72.2%
Liabilities, Current 4,650,248 USD +11.6%
Operating Lease, Liability, Noncurrent 4,834,348 USD -9.4%
Liabilities 9,484,596 USD -0.18%
Retained Earnings (Accumulated Deficit) -116,474,411 USD -13.4%
Stockholders' Equity Attributable to Parent 9,136,676 USD -60.6%
Liabilities and Equity 18,621,272 USD -43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3,447,911 USD +57.9%
Net Cash Provided by (Used in) Financing Activities -88,423 USD -2.3%
Net Cash Provided by (Used in) Investing Activities -4,947 USD +96.7%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 3,729,206 shares -88.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3,541,281 USD +57.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12,570,359 USD -45.7%
Depreciation 700,000 USD -12.5%
Payments to Acquire Property, Plant, and Equipment 13,447 USD -90.9%
Property, Plant and Equipment, Gross 291,384 USD -91.6%
Operating Lease, Liability, Current 500,817 USD -9.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital 125,610,714 USD -0.26%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense -239,714 USD -1.1%
Interest Expense 5,074 USD -78.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%